U.S. markets open in 8 hours 6 minutes

Nkarta, Inc. (NKTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
33.90-1.45 (-4.10%)
At close: 1:00PM EST
Sign in to post a message.
  • J
    James
    The first patient has been treated in the first-in-human PhI (n=27) trial of NKX101 for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes.

    The multi-centre trial is designed to evaluate safety, pharmacokinetics, and preliminary antitumour activity of NKX101 (NCT04623944).
  • J
    James
    Participation at upcoming investor conferences:

    Cowen 2020 IO Next Summit
    Date: Friday, November 13, 2020
    Fireside chat presentation: 11:45 a.m. ET

    Stifel 2020 Virtual Healthcare Conference
    Date: Tuesday, November 17, 2020
    Fireside chat presentation: 2:00 p.m. ET

    Evercore ISI 3RD Annual HealthCONx Conference
    Date: Tuesday, December 1, 2020
    Fireside chat presentation: 9:40 a.m. ET

    A live audio webcast of the events will be available on the Investors section of the website. A replay will be archived for approximately four weeks.
  • J
    James
    Cryopreserved NKX019 demonstrated potent, targeted antitumour activity in vitro and in vivo across different CD19+ types (B-cell lymphoma and acute lymphoblastic leukaemia). Compared to non-engineered NK cells, NKX019 resulted in increased treatment exposure and superior activity.

    Compared to an anti-CD19 CAR-T, NKX019 demonstrated a number of advantages. It was more potent on a per cell basis, and had a more rapid onset of activity. Moreover, when exposed to tumour cells side-by-side the product produced significantly lower quantities of factors associated with cytokine release syndrome, a type of adverse event associated with approved CAR-T cell therapies https://www.nkartatx.com/file.cfm/75/docs/Nkarta_SITC_2020_NKX019_pre-clinical_poster.pdf
  • Y
    Yahoo Finance Insights
    NKTX is up 11.07% to 33.00
  • Y
    Yahoo Finance Insights
    NKTX is up 10.91% to 29.98
  • R
    Richard
    Samo samo from Doc Cooper. Voting green.
  • J
    James
    SOUTH SAN FRANCISCO, Calif., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing...
    SOUTH SAN FRANCISCO, Calif., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing...
    www.globenewswire.com
  • Y
    Yahoo Finance Insights
    NKTX is down 11.73% to 25.70
  • S
    Shakes
    Wow! What happened on Friday - why the steep decline?
  • r
    rennels
    I started following "awesomestokcalerts" (Gooogle it - off course without any space or dash in between the words) and their notifications are better than anyone else.
  • Y
    Yahoo Finance Insights
    NKTX is down 11.37% to 29.77
  • J
    James
    In this paper the authors at MDA demonstrate that IL-15 secreting CAR-NK cells are subject to inhibition by the cytokine induced checkpoint CIS and that CRISPR KO improves the antitumour activity, and the metabolic fitness of the cells https://doi.org/10.1182/blood.2020007748
  • Y
    Yahoo Finance Insights
    NKTX is up 13.31% to 34.60
  • k
    kevin
    10000% an amazing buy I hope I?m able to #$%$ some up
  • T
    Tim
    How can come this wasn’t available at the $18 price?
  • E
    ExtremeProf
    NKARTA has amazing technology application... great potential... buy and hold.
    Bullish
  • J
    James
    Executive management plans to participate in a fireside chat at the Cantor Virtual Healthcare Conference on Tuesday, Sept 15, at 2:00 PM ET. A webcast of the event will be available on the investors section of the website.
  • k
    kevin
    Great long term investment
    Bullish
  • Y
    Yahoo Finance Insights
    NKTX is up 10.66% to 35.19
  • 7
    7:17
    timing and hoping to get in as soon as it starts trading